safety & risk profile

What We Know and Don't Know

TB-500's safety profile is poorly characterized in humans because no formal human safety trials have been completed for injectable use. what we know comes from animal toxicology studies, the RGN-259 ophthalmic safety data (topical, not injectable), and community-reported adverse events. the most significant theoretical concern is whether a peptide that promotes angiogenesis and cell migration could also promote tumor growth or metastasis -- a question that remains unresolved.